Celltrion’s biosimilar marketing strategy in Europe has got seriously confusing after the firm asked to market its rituximab near-copy under four different brands.
Johnson & Johnson is hoping its new acquisition Actelion will help stave off the effects of a price squeeze in the US, and a cheaper biosimilar of its bestseller, Remicade.
NHS authorities could begin to use the reimbursement system as a “stick” to ensure doctors prescribe cheaper biosimilar medicines amid varied uptake in different regions.
